Why Abbvie May Have A Tough Time Defending Humira ' s Price Before Congress

Drug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today.

Source: Forbes.com Healthcare News - February 26, 2019 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NYSE:ABT NYSE:ABBV NYSE:JNJ NYSE:BMY NYSE:PFE Source Type: news